Journal
CURRENT NEUROPHARMACOLOGY
Volume 21, Issue 12, Pages 2563-2566Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1570159X21666230803161825
Keywords
Ofatumumab; b-cells; immunophenotype; multiple sclerosis; immunological cells subset; anti-CD20
Categories
Ask authors/readers for more resources
The study aimed to investigate the changes in cellular subsets of patients with relapsing Multiple Sclerosis (RMS) before and after treatment with Ofatumumab. The results showed an increase in CD3+ T cell frequencies and a significant decrease in B naive cells after 4 and 12 weeks of treatment.
Background: Ofatumumab (OFA) is a fully human anti-CD20 monoclonal antibody administered with a 20 mg subcutaneous monthly dosing regimen.Methods: Inclusion criteria were patients: 1) aged 18-55; 2) with a confirmed diagnosis of relapsing Multiple Sclerosis (RMS), per the revised 2010 McDonald criteria; 2) who started OFA according to Italian Medicines Agency prescription rules and within 12 months from the RMS diagnosis; 3) naive to any disease-modifying therapy. The primary outcome was to offer an overview of cellular subsets of RMS naive patients (time 0) and then after 4 weeks (time 1) and 12 weeks (time 2) on therapy with OFA in a real-world setting.Results: Fifteen patients were enrolled. CD3+ T cell frequencies were higher at time 1 (%80.4, SD 7.7) and time 2 (%82.6, SD 5.8) when compared to time 0 (%72.4, SD 9.8), p = .013. B naive cells were barely detectable in the OFA group at time 1 (%0.4, SD 0.5) and 2 (%1.4, SD 2.9) when compared to time 0 (%11.5, SD 3.8), p < .001.Conclusion: The progressive and increasing use of anti-CD20 drugs imposes the need for larger, prospective, real-world, long-term studies to characterize further immunophenotypes of patients with RMS treated with OFA.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available